Monica Serra

Dr. Monica Serra

Division of Geriatrics, Gerontology & Palliative Medicine, Department of Medicine, University of Texas Health Science Center at San Antonio and Geriatrics Research, Education & Clinical Center, South Texas Veterans Health Care System, San Antonio, TX, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2020 in Current Nutrition Reports
Verified
Journal Article
Closed access
PDF file
MSMonica Serra
Monica Serra
KDKathleen R. Dondero
Kathleen R. Dondero
DLDerrik Larkins
Derrik Larkins
ABAisling Burns
Aisling Burns
OAOdessa Addison
Odessa Addison

12 July 2022 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
MSMonica Serra
Monica Serra
CHCharlene E. Hafer-Macko
Charlene E. Hafer-Macko
RRRonna Robbins
Ronna Robbins
JOJason C. O'COnnor
Jason C. O'COnnor
ARAlice S. Ryan
Alice S. Ryan

21 February 2020 in Disability and Health Journal
Verified
Journal Article
Closed access
RBRyan R. Bailey
Ryan R. Bailey
MSMonica Serra
Monica Serra
RMRyan McGrath
Ryan McGrath

1 December 2020 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MSMonica Serra
Monica Serra
VKVijaya Kancherla
Vijaya Kancherla
AKAnjali Khakharia
Anjali Khakharia
LALatricia L. Allen
Latricia L. Allen
LPLawrence S. Phillips
Lawrence S. Phillips
CVCamille P. Vaughan
Camille P. Vaughan

19 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MSMonica Serra
Monica Serra
Alice RyanAlice Ryan
Alice Ryan
The purpose of this study was to compare changes in bone mineral density (BMD) over a 6 month follow up (period of weight regain) in overweight, postmenopausal women having previously completed a 6 month weight loss (WL) intervention with and without aerobic exercise (AEX). Women (BMI > 25 kg/m2) underwent VO2max and DEXA scans at baseline, after 6 months of WL or AEX + WL, and at 12 months ad libitum follow up. Both groups lost ~9% body weight from 0 to 6 months and regained ~2% from 6 to 12 months, while losing ~4% of appendicular lean mass (ALM) across the 12-month study duration. VO2max increased 10% from 0 to 6 months and declined 12% from 6 to 12 months for AEX + WL, with no changes for WL. Total body (p < 0.01) and total femur (p = 0.03) BMD decreased similar between groups across time (combined groups: 0–6 months: total body: −1.2% and total femur: −1.2%; 6–12 months: total body: −0.26% and total femur: −0.09%). Less ALM loss and greater VO2max increases during the WL phase were associated with attenuated BMD loss at various anatomical sites during periods of weight regain (6–12 months) p’s < 0.05). Results suggest that BMD loss may continue following WL, despite weight regain. Further, this study adds to the literature by suggesting that preventing declines in muscle quality and function during WL may attenuate the loss of BMD during weight regain. Future studies are needed to identify mechanisms underlying WL-induced bone loss so that effective practices can be designed to minimize the loss of BMD during WL and weight maintenance in older women.

13 September 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
TCTiffany M Cortes
Tiffany M Cortes
LVLibia Vasquez
Libia Vasquez
MSMonica Serra
Monica Serra
RRRonna Robbins
Ronna Robbins
ASAllison Stepanenko
Allison Stepanenko
NMNicolas Musi
Nicolas Musi
Background: Older adults with type 2 diabetes mellitus (T2DM) or prediabetes are at increased risk of adverse changes in body composition, physical function, and aging-related biomarkers compared to those with normal glucose tolerance. Semaglutide is a glucagon-like peptide 1 receptor agonist that has been approved for T2DM and chronic weight management. Although semaglutide is effective for weight loss and T2DM management, its effects on lean body mass, physical function, and biomarkers of aging are understudied in older adults. Objective: This study aims to compare the effects of lifestyle counseling with and that without semaglutide on body composition, physical function, and biomarkers of aging in older adults. Methods: This is an open-label randomized controlled trial. A total of 20 adults (aged 65 years and older) with elevated BMI (27-40 kg/m2) and prediabetes or well-controlled T2DM (hemoglobin A1c 5.7%-7.5%) are recruited, stratified by sex, and randomized 1:1 to one of 2 groups (semaglutide plus lifestyle counseling vs lifestyle counseling alone) and followed up for 5 months. Those in the semaglutide group are titrated to 1 mg weekly, as tolerated, for 12 weeks. Lifestyle counseling is given by registered dietitians and based on the Diabetes Prevention Program Lifestyle Change Program. Our primary outcomes include changes in lean mass, physical function, and biomarkers of aging. Body composition is measured by dual-energy x-ray absorptiometry and includes total fat mass and lean mass. Physical function is measured by 6-minute walk distance, grip strength, and short physical performance battery. Biomarkers of aging are measured in blood, skeletal muscle, and abdominal adipose tissue to include C-reactive protein, interleukin-6, tumor necrosis factors α, and β galactosidase staining. Results: The study was funded in December 2021 with a projected data collection period from spring 2023 through summer 2024. Conclusions: Despite the elevated risk of adverse changes in body composition, physical function, and biomarkers of aging among older adults with glucose intolerance and elevated adiposity, the benefits and risks of commonly prescribed antihyperglycemic or weight loss medications such as semaglutide are understudied. This study aims to fill this knowledge gap to inform clinicians about the potential for additional clinically meaningful, nonglycemic effects of semaglutide. Trial Registration: ClinicalTrials.gov NCT05786521; https://clinicaltrials.gov/study/NCT05786521 International Registered Report Identifier (IRRID): DERR1-10.2196/62667